| Objective: The purpose of this study was to evaluate the effect of Dapagliflozin on the clinical efficacy and ventricular remodeling in patients with coronary heart disease after percutaneous coronary intervention(PCI)complicated with type 2 diabetes through changes in serum remodeling biomaker Galectin-3,general serological indexes,and cardiac ultrasound.Methods: A total of 77 patients with coronary heart disease after PCI complicated with type 2 diabetes who were admitted to the Second Department of Cardiac Vascular and General Department of Shaanxi Provincial People’s Hospital from June 2019 to June 2020 were selected(PCI was performed within 1 year),according to the different treatment options,the patients were randomly divided into observation group(n=40)and control group(n=37).Observation group was given a hypoglycemic regimen containing Dapagliflozin(10mg once a day);The control group was given a hypoglycemic regimen without Dapagliflozin.Based on the indications for Dapagliflozin,Metformin and/or insulin were the other hypoglycemic agents in both groups.Blood glucose in both groups reached the standard during treatment,after 24 weeks of treatment body mass index(BMI),cardiac ultrasonography: Left ventricular ejection fraction(LVEF),Left ventricular end-systolic diameter(LVESD),Left ventricular end diastolic diameter(LVEDD),clinical serological indexes: fasting blood-glucose(FBG),glycosylated hemoglobin A1c(HbA1c),blood lipid,serum β-HB,hepatic and renal function,interleukin 6(IL-6),urine protein,urine glucose and other clinical indexes were collected before and after treatment in two groups.Blood samples were collected before and after treatment to detect serum galectin-3 levels by ELISA.At the same time,recording the adverse cardiac events and adverse reactions during medication.The experimental data were statistically analyzed by t-test and chi-square test.Results:1.The observation group compared to the control group,baseline medicine rates,complicated underlying disease,Galectin-3,IL-6,BMI,FBG,Hb A1 c,blood lipid,serum,β-HB,hepatic and renal function,LVEF,LVEDD,LVESD,urine protein,urine glucose and other indicators had no statistical significance(P>0.05);2.After 24 weeks of treatment,the laboratory indicators of Galectin-3,IL-6 and uric acid in the observation group were significantly lower than those in the control group,and the changes were statistically different(P<0.05);The positive rate of urine sugar in the observation group was higher than that in the control group(P=0.000),this is related to the Dapagliflozin action principle;In ultrasound,compared with the control group,LVEDD and LVESD were decreased with statistical difference(P<0.05),There was no significant difference between LVEF groups,but the observation group was significantly higher than before treatment.There was no statistical difference in the remaining serological indexes between the observation group and the control group(P>0.05);3.During treatment,there was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusions: Based on the results of serological and cardiac tests,in patients with coronary heart disease after PCI complicated with type 2 diabetes,compared with basic hypoglycemic drugs(Metformin and Insulin),Dapagliflozin has certain effects on improving ventricular remodeling,reducing inflammatory factors and reducing uric acid under the condition that blood glucose control is up to standard. |
PDF Full Text Request